JCIA
PTGX icon

Jackson Creek Investment Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Jackson Creek Investment Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59M Buy
+11,610
New +$1.21M 0.53% 49
2024
Q4 		– Sell
-44,685
Closed -$2.01M – 349
2024
Q3 		$2.01M Buy
44,685
+10,034
+29% +$405K 0.6% 14
2024
Q2 		$1.2M Sell
34,651
-61
-0.2% -$1.79K 0.44% 62
2024
Q1 		$1M Buy
+34,712
New +$944K 0.36% 155

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Jackson Creek Investment Advisors's PTGX Position: Q2 2026 in Review

Jackson Creek Investment Advisors opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 11,610 shares worth $1.59M. The stake represents 0.53% of the portfolio and ranks #49 among its holdings. This is a return to the name: Jackson Creek Investment Advisors previously reported a position in PTGX as recently as Q3 2024.

Jackson Creek Investment Advisors first reported a position in PTGX in Q1 2024 and has held it in 4 quarters since. The position peaked at $2.01M in Q3 2024. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Jackson Creek Investment Advisors held 11,610 shares of Protagonist Therapeutics worth $1.59M as of Q2 2026.
  • Protagonist Therapeutics was a new Jackson Creek Investment Advisors position in Q2 2026.
  • Protagonist Therapeutics made up 0.53% of Jackson Creek Investment Advisors's portfolio in Q2 2026, its #49 holding.
  • Jackson Creek Investment Advisors first reported a position in Protagonist Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • Jackson Creek Investment Advisors's Protagonist Therapeutics position peaked at $2.01M in Q3 2024.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Jackson Creek Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.